DOCSLIB.ORG

Genome-Wide Association Studies

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Genome-Wide Association Studies PRIMER Genome- wide association studies Emil Uffelmann 1, Qin Qin Huang 2, Nchangwi Syntia Munung 3, Jantina de Vries3, Yukinori Okada 4,5, Alicia R. Martin6,7,8, Hilary C. Martin2, Tuuli Lappalainen9,10,12 and Danielle Posthuma 1,11 ✉ Abstract | Genome-wide association studies (GWAS) test hundreds of thousands of genetic variants across many genomes to find those statistically associated with a specific trait or disease. This methodology has generated a myriad of robust associations for a range of traits and diseases, and the number of associated variants is expected to grow steadily as GWAS sample sizes increase. GWAS results have a range of applications, such as gaining insight into a phenotype’s underlying biology, estimating its heritability, calculating genetic correlations, making clinical risk predictions, informing drug development programmes and inferring potential causal relationships between risk factors and health outcomes. In this Primer, we provide the reader with an introduction to GWAS, explaining their statistical basis and how they are conducted, describe state- of- the art approaches and discuss limitations and challenges, concluding with an overview of the current and future applications for GWAS results. Polygenic risk scores Genome- wide association studies (GWAS) aim to iden- be allowed for clinical use as a stratification tool and a 7 (PRSs). Scores that provide tify associations of genotypes with phenotypes by testing genetically based biomarker . an indication of an individual’s for differences in the allele frequency of genetic variants More than 5,700 GWAS have now been conducted genetic liability to a trait or between individuals who are ancestrally similar but dif- for more than 3,300 traits8 and a push for more statistical disease, calculated using an individual’s genome, weighted fer phenotypically. GWAS can consider copy- number power has thrust GWAS sample sizes well beyond a mil- 9,10 by effect sizes obtained from variants or sequence variations in the human genome, lion participants , yielding numerous associated and genome- wide association although the most commonly studied genetic variants replicable variants for many heritable traits. Now that studies (GWAS). in GWAS are single- nucleotide polymorphisms (SNPs). reliable genetic associations for various phenotypes are GWAS typically report blocks of correlated SNPs that all known, we are faced with the next big challenge: inter- Linkage disequilibrium The non- independent show a statistically significant association with the trait preting these associations in a biological and genomic association of two alleles of interest, known as genomic risk loci. After 15 years of context. Previous GWAS have shown that most traits are in a population. GWAS 1, many replicated genomic risk loci have been influenced by thousands of causal variants11 that indi- associated with diseases and traits1, such as FTO2 for vidually confer very little risk, are often associated with obesity and PTPN22 (REF.3) for autoimmune diseases. many other traits8 and are correlated with causal and These results have sometimes provided hints into dis- non- causal variants that are physically close as a result ease biology; for example, a GWAS implicated the of linkage disequilibrium12, making direct biological, causal IL-12/IL-23 pathway in the development of Crohn’s inferences complicated13. Further, genetic associations disease4, which supported subsequent clinical trials for may differ across ancestries, complicating direct compar- drugs targeting the IL-12/IL-23 pathway5. isons between groups of individuals. Some of these limi- Results from GWAS can be used for a range of appli- tations hamper drawing unambiguous conclusions about cations. For example, trait- associated genetic variants the biological meaning of GWAS results, sometimes lim- can be used as control variables in epidemiology studies iting their utility to produce mechanistic insights or to to account for confounding genetic group differences6. serve as starting points for drug development1. Further, results can be used to predict an individual’s risk In this Primer, we aim to provide the reader with a for physical and mental disease based on their genetic comprehensive overview of GWAS, covering practical profile. Indeed, a recent study showed that genomic considerations, such as experimental design, robust risk prediction using genome- wide polygenic risk scores data analysis and data deposition, ethical implications (PRSs) for coronary artery disease, atrial fibrillation, and reproducibility of results. We also provide guidance type 2 diabetes, inflammatory bowel disease and breast on how to interpret results from GWAS using several ✉e- mail: [email protected] cancer can identify disease risk as well as monogenic post- GWAS strategies and functional follow- up exper- https://doi.org/10.1038/ risk prediction strategies based on rare, highly pene- iments, as well as a discussion of the above- mentioned s43586-021-00056-9 trant mutations7. Genomic risk prediction may soon limitations and future challenges of GWAS. NATURE REVIEWS | METHODS PRIMERS | Article citation ID: (2021) 1:59 1 0123456789();: PRIMER Author addresses sample size, the experimental question and the availabil- ity of pre- existing data or the ease with which new data 1 Department of Complex Trait Genetics, Center for Neurogenomics and Cognitive can be collected. GWAS can be conducted using Research, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam, data from resources such as biobanks or cohorts with Netherlands. disease- focused or population- based recruitment, or 2Human Genetics Programme, Wellcome Sanger Institute, Wellcome Genome Campus, Hinxton, UK. through direct to consumer studies. Assembling data 3Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa. sets of a sufficient size to run a well-powered GWAS for 4Department of Statistical Genetics, Osaka University Graduate School of Medicine, a complex trait requires major investments of time and Osaka, Japan. money that go beyond the capacity of most individual 5Laboratory of Statistical Immunology, Immunology Frontier Research Center laboratories. However, there are several excellent public (WPI- IFReC), Osaka University, Osaka, Japan. resources available that provide access to large cohorts 6Analytic & Translational Genetics Unit, Massachusetts General Hospital, Boston, MA, with both genotypic and phenotypic information, and the USA. majority of GWAS are conducted using these pre-existing 7 Program in Medical and Population Genetics, Broad Institute of MIT and Harvard, resources. Even when new data have been collected in- Cambridge, MA, USA. house, these will typically be co-analysed with data from 8Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, MA, USA. pre- existing resources; collecting new data is usually 9New York Genome Center, New York, NY, USA. required when more refined phenotyping is desired. 10Department of Systems Biology, Columbia University, New York, NY, USA. For all study designs, recruitment strategies must be 11Department of Child and Adolescent Psychiatry and Pediatric Psychology, Section carefully considered as these can induce collider bias and Complex Trait Genetics, Amsterdam Neuroscience, Vrije Universiteit Medical Center, other forms of bias in the resultant data16. For example, Amsterdam, Netherlands. widely used research cohorts such as the UK Biobank 12Science for Life Laboratory, Department of Gene Technology, KTH Royal Institute of recruit participants through a volunteer- based strategy, Technology, Stockholm, Sweden. which results in participants who are, on average, health- ier, wealthier and more educated than the general popu- Experimentation lation17. Further, cohorts that enrol participants from The experimental workflow of a GWAS involves several hospitals based on their disease status (such as BioBank steps, including the collection of DNA and phenotypic Japan) will have different selection biases to cohorts information from a group of individuals (such as dis- recruited from the general population18. Different eth- ease status and demographic information such as age nicities can be included in the same study, as long as and sex); genotyping of each individual using available the population substructure is considered to avoid false GWAS arrays or sequencing strategies; quality control; positive results. Individual cohorts with detailed clinical imputation of untyped variants using haplotype phasing measures may not be able to meet the required sample and reference populations; conducting the statistical test size; in these cases, ‘proxy’ phenotypes that are easier to for association; conducting a meta- analysis (optional); measure and for which there are more data can be used seeking an independent replication; and interpreting (for example, educational attainment can be used as a the results by conducting multiple post- GWAS analyses proxy for intelligence, or depressive symptoms can be (FIG. 1). At each step, possible biases and errors may enter used as a proxy for a clinical diagnosis of depression)19. the study, and therefore careful planning is required when setting up a GWAS, and adherence to standard- Genotyping. Genotyping of individuals is typically ized quality control and analysis protocols is advised. We done using microarrays for common variants or next- detail these steps below. We note that most of the issues generation sequencing methods such
Load more

Recommended publications
  • Whole Genome Sequencing Identifies Novel Structural Variant in a Large Indian Family Affected with X - Linked Agammaglobulinemia
    medRxiv preprint doi: https://doi.org/10.1101/2020.10.05.20200949; this version posted October 6, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license . Whole Genome Sequencing identifies novel structural variant in a large Indian family affected with X - linked agammaglobulinemia 1,2,# 3,5,#,$ 3,4 3 Abhinav Jain ,​ Geeta Madathil Govindaraj ,​ Athulya Edavazhippurath ,​ Nabeel Faisal ,​ Rahul C ​ ​ ​ ​ 1 1,2 6 3 1 1 Bhoyar ,​ Vishu Gupta ,​ Ramya Uppuluri ,​ Shiny Padinjare Manakkad ,​ Atul Kashyap ,​ Anoop Kumar ,​ ​ ​ ​ ​ ​ ​ 1,2 1,2 7 7 3 Mohit Kumar Divakar ,​ Mohamed Imran ,​ Sneha Sawant ,​ Aparna Dalvi ,​ Krishnan Chakyar ,​ ​ ​ ​ ​ ​ 7 6 1,2,$ 1,2,$ Manisha Madkaikar ,​ Revathi Raj ,​ Sridhar Sivasubbu ,​ Vinod Scaria ​ ​ ​ ​ 1 CSIR-Institute​ of Genomics and Integrative Biology, Mathura Road, New Delhi, Delhi, India 2 Academy​ of Scientific and Innovative Research (AcSIR), Mathura Road, New Delhi, Delhi, India 3 Department​ of Pediatrics, Government Medical College Kozhikode, Kozhikode, Kerala, India 4 Multidisciplinary​ Research Unit, Government College Kozhikode, Kozhikode, Kerala, India 5 FPID​ Regional Diagnostic Centre, Government Medical College Kozhikode, Kozhikode, Kerala India 6 Department​ of Pediatric Hematology, Oncology, Blood and Marrow Transplantation, Apollo Hospitals, 320, Padma complex, Anna salai, Teynampet, Chennai, Tamil Nadu, India 7 Department​ of Pediatric Immunology and Leukocyte Biology, ICMR-National Institute of Immunohaematology, KEM Hospital, Parel, Mumbai, Maharashtra, India. # Joint first authors $ Corresponding author Vinod Scaria: [email protected] ​ Sridhar Sivasubbu: [email protected] ​ Geeta Madathil Govindaraj: [email protected] ​ NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.
    [Show full text]
  • The Precision Medicine Issue Medicine Is Becoming Hyper
    The precision medicine issue Vol. 121 Nov/Dec $9.99 USD No. 6 2018 $10.99 CAD $2 million would save her life. The precision medicine issue Could you pay? Should you? Medicine is becoming hyper-personalized, hyper-accurate ... and hyper-unequal. p.38 The AIs taking over Curing cancer How to plan your from doctors with customized digital afterlife vaccines p.22 p.46 p.76 ND18_cover.indd 1 10/3/18 4:16 PM Artificial intelligence is here. Own what happens next. ND18 ETD19 Spread 16x10.875 D3.indd 2 9/28/18 10:59 AM March 25–26, 2019 St. egis Hotel San Francisco, CA Meet the people leading the next wave of intelligent technologies. Andrew Kathy Daphne Sergey Harry Anagnost Gong Koller Levine Shum President and Cofounder and Founder and Assistant Executive Vice CEO, Autodesk CEO, WafaGames CEO, Insitro Professor, EECS, President, UC Berkeley Microsoft Artifi cial Intelligence and Research Group EmTechDigital.com/2019 ND18 ETD19 Spread 16x10.875 D3.indd 3 9/28/18 10:59 AM 02 From the editor It’s been nearly two decades since the help meet the ballooning healthcare first human genome was sequenced. needs of an aging population. That achievement opened up the prom The problem? As medicine gets ise of drugs and treatments perfectly more personalized, it risks getting more tailored to each person’s DNA. But per unequal. Our cover story is Regalado’s sonalized or “precision” medicine has gripping and troubling account page always felt a bit like flying cars, sexbots, 38 of the parents who raise millions of or labgrown meat­one of those things dollars to finance genetherapy cures for we’re perpetually being promised but their children’s ultrarare diseases.
    [Show full text]
  • Exome Sequencing and Functional Validation in Zebrafish Identify
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector REPORT Exome Sequencing and Functional Validation in Zebrafish Identify GTDC2 Mutations as a Cause of Walker-Warburg Syndrome M. Chiara Manzini,1,2 Dimira E. Tambunan,1,2 R. Sean Hill,1,2 Tim W. Yu,1,2 Thomas M. Maynard,3 Erin L. Heinzen,4 Kevin V. Shianna,4 Christine R. Stevens,5 Jennifer N. Partlow,1,2 Brenda J. Barry,1,2 Jacqueline Rodriguez,1,2 Vandana A. Gupta,1,6 Abdel-Karim Al-Qudah,7 Wafaa M. Eyaid,8 Jan M. Friedman,9,10 Mustafa A. Salih,11 Robin Clark,12 Isabella Moroni,13 Marina Mora,14 Alan H. Beggs,1,6 Stacey B. Gabriel,5 and Christopher A. Walsh1,2,5,* Whole-exome sequencing (WES), which analyzes the coding sequence of most annotated genes in the human genome, is an ideal approach to studying fully penetrant autosomal-recessive diseases, and it has been very powerful in identifying disease-causing muta- tions even when enrollment of affected individuals is limited by reduced survival. In this study, we combined WES with homozygosity analysis of consanguineous pedigrees, which are informative even when a single affected individual is available, to identify genetic mutations responsible for Walker-Warburg syndrome (WWS), a genetically heterogeneous autosomal-recessive disorder that severely affects the development of the brain, eyes, and muscle. Mutations in seven genes are known to cause WWS and explain 50%–60% of cases, but multiple additional genes are expected to be mutated because unexplained cases show suggestive linkage to diverse loci.
    [Show full text]
  • Genomic Approaches for Understanding the Genetics of Complex Disease
    Downloaded from genome.cshlp.org on September 25, 2021 - Published by Cold Spring Harbor Laboratory Press Perspective Genomic approaches for understanding the genetics of complex disease William L. Lowe Jr.1 and Timothy E. Reddy2,3 1Division of Endocrinology, Metabolism and Molecular Medicine, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois 60611, USA; 2Department of Biostatistics and Bioinformatics, Duke University Medical School, Durham, North Carolina 27708, USA; 3Center for Genomic and Computational Biology, Duke University Medical School, Durham, North Carolina 27708, USA There are thousands of known associations between genetic variants and complex human phenotypes, and the rate of novel discoveries is rapidly increasing. Translating those associations into knowledge of disease mechanisms remains a fundamental challenge because the associated variants are overwhelmingly in noncoding regions of the genome where we have few guiding principles to predict their function. Intersecting the compendium of identified genetic associations with maps of regulatory activity across the human genome has revealed that phenotype-associated variants are highly enriched in candidate regula- tory elements. Allele-specific analyses of gene regulation can further prioritize variants that likely have a functional effect on disease mechanisms; and emerging high-throughput assays to quantify the activity of candidate regulatory elements are a promising next step in that direction. Together, these technologies have created the ability to systematically and empirically test hypotheses about the function of noncoding variants and haplotypes at the scale needed for comprehensive and system- atic follow-up of genetic association studies. Major coordinated efforts to quantify regulatory mechanisms across genetically diverse populations in increasingly realistic cell models would be highly beneficial to realize that potential.
    [Show full text]
  • QTL Analysis Reveals Genomic Variants Linked to High-Temperature
    Wang et al. Biotechnol Biofuels (2019) 12:59 https://doi.org/10.1186/s13068-019-1398-7 Biotechnology for Biofuels RESEARCH Open Access QTL analysis reveals genomic variants linked to high-temperature fermentation performance in the industrial yeast Zhen Wang1,2†, Qi Qi1,2†, Yuping Lin1*, Yufeng Guo1, Yanfang Liu1,2 and Qinhong Wang1* Abstract Background: High-temperature fermentation is desirable for the industrial production of ethanol, which requires thermotolerant yeast strains. However, yeast thermotolerance is a complicated quantitative trait. The understanding of genetic basis behind high-temperature fermentation performance is still limited. Quantitative trait locus (QTL) map- ping by pooled-segregant whole genome sequencing has been proved to be a powerful and reliable approach to identify the loci, genes and single nucleotide polymorphism (SNP) variants linked to quantitative traits of yeast. Results: One superior thermotolerant industrial strain and one inferior thermosensitive natural strain with distinct high-temperature fermentation performances were screened from 124 Saccharomyces cerevisiae strains as parent strains for crossing and segregant isolation. Based on QTL mapping by pooled-segregant whole genome sequencing as well as the subsequent reciprocal hemizygosity analysis (RHA) and allele replacement analysis, we identifed and validated total eight causative genes in four QTLs that linked to high-temperature fermentation of yeast. Interestingly, loss of heterozygosity in fve of the eight causative genes including RXT2, ECM24, CSC1, IRA2 and AVO1 exhibited posi- tive efects on high-temperature fermentation. Principal component analysis (PCA) of high-temperature fermentation data from all the RHA and allele replacement strains of those eight genes distinguished three superior parent alleles including VPS34, VID24 and DAP1 to be greatly benefcial to high-temperature fermentation in contrast to their inferior parent alleles.
    [Show full text]
  • A Comprehensive Database of Putative Human Microrna Target Site
    bioRxiv preprint doi: https://doi.org/10.1101/554485; this version posted May 26, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. dbMTS: a comprehensive database of putative human microRNA target site SNVs and their functional predictions Chang Li1,2, Michael D. Swartz3, Bing Yu1, Yongsheng Bai4, Xiaoming Liu1,2* 1Human Genetics Center and Department of Epidemiology, Human Genetics and Environmental Sciences, School of Public Health, The University of Texas Health Science Center at Houston, Houston, TX 2USF Genomics, College of Public Health, University of South Florida, Tampa, FL 3Department of Biostatistics, School of Public Health, The University of Texas Health Science Center at Houston, Houston, TX 4Department of Internal Medicine, University of Michigan, Ann Arbor, MI *Correspondence: Xiaoming Liu, [email protected] Funding information: This work is supported partially by NIH funding 1UM1HG008898 and partially by the startup funding for XL from the University of South Florida. bioRxiv preprint doi: https://doi.org/10.1101/554485; this version posted May 26, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. Abstract microRNAs (miRNAs) are short non-coding RNAs that can repress the expression of protein coding messenger RNAs (mRNAs) by binding to the 3’UTR of the target.
    [Show full text]
  • Interleukin 10 Mutant Zebrafish Have an Enhanced Interferon
    www.nature.com/scientificreports OPEN Interleukin 10 mutant zebrafsh have an enhanced interferon gamma response and improved Received: 22 August 2017 Accepted: 20 June 2018 survival against a Mycobacterium Published: xx xx xxxx marinum infection Sanna-Kaisa E. Harjula1, Markus J. T. Ojanen1,2, Sinja Taavitsainen3, Matti Nykter3 & Mika Rämet1,4,5,6 Tuberculosis ranks as one of the world’s deadliest infectious diseases causing more than a million casualties annually. IL10 inhibits the function of Th1 type cells, and IL10 defciency has been associated with an improved resistance against Mycobacterium tuberculosis infection in a mouse model. Here, we utilized M. marinum infection in the zebrafsh (Danio rerio) as a model for studying Il10 in the host response against mycobacteria. Unchallenged, nonsense il10e46/e46 mutant zebrafsh were fertile and phenotypically normal. Following a chronic mycobacterial infection, il10e46/e46 mutants showed enhanced survival compared to the controls. This was associated with an increased expression of the Th cell marker cd4-1 and a shift towards a Th1 type immune response, which was demonstrated by the upregulated expression of tbx21 and ifng1, as well as the down-regulation of gata3. In addition, at 8 weeks post infection il10e46/e46 mutant zebrafsh had reduced expression levels of proinfammatory cytokines tnf and il1b, presumably indicating slower progress of the infection. Altogether, our data show that Il10 can weaken the immune defense against M. marinum infection in zebrafsh by restricting ifng1 response. Importantly, our fndings support the relevance of M. marinum infection in zebrafsh as a model for tuberculosis. Annually more than 10 million new tuberculosis cases are estimated to emerge, leading to over a million casualties1.
    [Show full text]
  • Daniel J. Benjamin (As of 10/4/2019)
    Daniel J. Benjamin (as of 10/4/2019) Contact Information University of Southern California Center for Economic and Social Research Dauterive Hall 635 Downey Way, Suite 301 Los Angeles, CA 90089-3332 Phone: 617-548-8948 Professional Experience: Professor (Research) of Economics, CESR, USC, 2019-present Associate Professor (Research) of Economics, CESR, USC, 2015-2019 Visiting Associate Professor (Research) of Economics, CESR, USC, 2014-2015 Associate Professor (with tenure), Economics Department, Cornell University, 2013-2015 Assistant Professor, Economics Department, Cornell University, 2007-2013 Visiting Research Fellow, National Bureau of Economic Research (NBER), 2011-2012 Research Associate, NBER, 2013-present Faculty Research Fellow, NBER, 2009-2013 Research Fellow, Research Center for Group Dynamics, Institute for Social Research, 2006-2017 Research Fellow, Population Studies Center, Institute for Social Research, 2006-2007 Graduate Studies: Ph.D., Economics, Harvard University, 2006 M.Sc., Mathematical Economics, London School of Economics, 2000 A.M., Statistics, Harvard University, 1999 Undergraduate Studies: A.B., Economics, Harvard University, summa cum laude, prize for best economics student, 1999 Honors, Scholarships, and Fellowships: 2013 Norwegian School of Economics Sandmo Junior Fellowship (prize for a “promising young economist”) 2012-2013 Cornell’s Institute for Social Science (ISS) Faculty Fellowship 2009-2012 ISS Theme Project Member: Judgment, Decision Making, and Social Behavior 2011-2012 NBER Visiting Fellowship
    [Show full text]
  • Comparison of Structural and Short Variants Detectedby Linked-Read
    cancers Article Comparison of Structural and Short Variants Detected by Linked-Read and Whole-Exome Sequencing in Multiple Myeloma Ashwini Kumar 1,2 , Sadiksha Adhikari 1,2, Matti Kankainen 2,3,4,5 and Caroline A. Heckman 1,2,* 1 Institute for Molecular Medicine Finland-FIMM, HiLIFE-Helsinki Institute of Life Science, iCAN Digital Cancer Medicine Flagship, University of Helsinki, Tukholmankatu 8, 00290 Helsinki, Finland; ashwini.kumar@helsinki.fi (A.K.); sadiksha.adhikari@helsinki.fi (S.A.) 2 iCAN Digital Precision Cancer Medicine, University of Helsinki, 00014 Helsinki, Finland; matti.kankainen@helsinki.fi 3 Medical and Clinical Genetics, University of Helsinki, Helsinki University Hospital, 00029 Helsinki, Finland 4 Translational Immunology Research Program and Department of Clinical Chemistry, University of Helsinki, 00290 Helsinki, Finland 5 Hematology Research Unit Helsinki, Department of Hematology, Helsinki University Hospital Comprehensive Cancer Center, 00290 Helsinki, Finland * Correspondence: caroline.heckman@helsinki.fi; Tel.: +358-29-412-5769 Simple Summary: The wide variety of next-generation sequencing technologies requires thorough evaluation and understanding of their advantages and shortcomings of these different approaches prior to their implementation in a precision medicine setting. Here, we compared the performance of two DNA sequencing methods, whole-exome and linked-read exome sequencing, to detect large Citation: Kumar, A.; Adhikari, S.; structural variants (SVs) and short variants in eight multiple myeloma (MM) patient cases. For three Kankainen, M.; Heckman, C.A. patient cases, matched tumor-normal samples were sequenced with both methods to compare somatic Comparison of Structural and Short SVs and short variants. The methods’ clinical relevance was also evaluated, and their sensitivity Variants Detected by Linked-Read and specificity to detect MM-specific cytogenetic alterations and other short variants were measured.
    [Show full text]
  • Variant Annotation
    Variant annotation Theorical part V1.1 10/10/18 Ready for annotating variants!! Variant annotation and prioritization Annotation Databases Eilbeck, Karen & Quinlan, Aaron & Yandell, Mark. (2017). Settling the score: variant prioritization and Mendelian disease. Nature Reviews Genetics. 10.1038/nrg.2017.52. Genomic data repositories - 1000 Genomes The 1000 Genomes Project (abbreviated as 1KGP), launched in January 2008, was an international research effort to establish by far the most detailed catalogue of human genetic variation. - ESP (NHLBI Exome Sequencing Project) Exists in 3 flavours : evs annotation data was generated from approximately 2500 exomes, evs_5400 from approximately 5400 exomes and the last one, evs_6500 from approximately 6500 exomes - ExAC (Exome Aggregation Consortium) Coalition of investigators seeking to aggregate and harmonize exome sequencing data from a variety of large-scale sequencing projects, and to make summary data available for the wider scientific community. - gnomAD (Genome Aggregation Database) Developed by an international coalition of investigators, with the goal of aggregating and harmonizing both exome and genome sequencing data from a wide variety of large-scale sequencing projects. - FREX (THE FRENCH EXOME) A REFERENCE PANEL OF EXOMES FROM FRENCH REGIONS Annotation Databases Eilbeck, Karen & Quinlan, Aaron & Yandell, Mark. (2017). Settling the score: variant prioritization and Mendelian disease. Nature Reviews Genetics. 10.1038/nrg.2017.52. Databases of variant-disease and gene-disease associations
    [Show full text]
  • 1 Mapping Challenging Mutations by Whole-Genome Sequencing Harold
    bioRxiv preprint doi: https://doi.org/10.1101/036046; this version posted January 6, 2016. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC 4.0 International license. Mapping challenging mutations by whole-genome sequencing Harold E. Smith, Amy S. Fabritius, Aimee Jaramillo-Lambert, and Andy Golden National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland 20892 1 bioRxiv preprint doi: https://doi.org/10.1101/036046; this version posted January 6, 2016. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC 4.0 International license. Running title: Challenging mutations by WGS Keywords: Forward genetics, variant detection, complex alleles, SNP mapping Corresponding author: Harold E. Smith 8 Center Drive Bethesda, MD 20892 301-594-6554 [email protected] 2 bioRxiv preprint doi: https://doi.org/10.1101/036046; this version posted January 6, 2016. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC 4.0 International license. ABSTRACT Whole-genome sequencing provides a rapid and powerful method for identifying mutations on a global scale, and has spurred a renewed enthusiasm for classical genetic screens in model organisms.
    [Show full text]
  • Phase 3. Functional Variant Discovery
    Phase 3. Functional Variant Discovery Introduction There is no single ‘recipe’ for identifying functional variants. Every filtering strategy inevitably starts with multiple often-logical assumptions about the properties of causal variants that may also discard candidates too early. Novelty is one example, where the variant is not expected to be present in public repositories, even though apparently healthy individuals carrying it may have been sequenced in unrelated studies. High predicted functional impact is another, where a variant is expected to simultaneously occur at an evolutionarily conserved genomic location and also be scored as deleterious by multiple predictive algorithms may even be too stringent a rule in a Mendelian trait. In a similar vein, in a population genetics study, a novel amino acid class-changing variant that is not predicted to have a functional effect by the standard tools may have a molecular effect. An inheritance model may itself be incorrect, e.g. a condition may be autosomal recessive rather than X-linked as hypothesized, or digenic rather than recessive, etc. It is therefore important not to conclude too early that the variant(s) of interest “are not in the exome” and to exhaust all alternate plausible rules and scenarios before that conclusion is reached. Using disease variant discovery as a context, we aim to present here a range of guidelines that can be used to develop an appropriate variant prioritisation strategy. This phase will be presented as 5 sub-phases: 1. Variant annotation - using ANNOVAR (Wang et al, 2010) as an example 2. Frequency 3. Case-control filtering 4. Variant class filtering 5.
    [Show full text]